Reply Feature Tracking Cardiac Magnetic Resonance Imaging in the Assessment of Left Atrial Function by Hoit, Brian D.
JACC Vol. 63, No. 22, 2014 Correspondence
June 10, 2014:2432–7
2435technique that tracks the myocardial wall by using cine CMR
images. With feature/tissue tracking CMRI, phasic LA volume,
LA strain and strain rate, and LA velocity can be measured using
cine images. In a recent study performed with 28 patients with
atrial ﬁbrillation, feature-tracking MRI was able to detect changes
in LA strain, strain rate, and velocity following catheter ablation
(2). Preliminary studies within the Multi-Ethnic Study of Ath-
erosclerosis have shown the usefulness of tissue-tracking–derived
LA strain and strain rate in patients with atrial ﬁbrillation (3),
heart failure (4), and myocardial infarction (5).
The results of studies of reproducibility and repeatability of feature-/
tissue-tracking methods of MRI have been mixed (6,7). Moreover,
studies of LA structure and function from feature-/tissue-tracking
CMRI speciﬁcally have been lacking. Although further technical im-
provements and more studies are required before feature-/tissue-
tracking MRI can be used routinely, it is, nevertheless, a valuable tool
for detailed assessment of phasic LA structure and function.*Mohammadali Habibi, MD
Bharath Ambale Venkatesh, PhD
João A. C. Lima, MD
*Johns Hopkins University
600 North Wolfe Street, Carnegie 546
Baltimore, Maryland 21287
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Magnetic Resonance
Imaging in the Assessment
of Left Atrial FunctionI appreciate the interest shown by Dr. Habibi and colleagues,
and thank them for their recent contributions to the ﬁeld of left
atrial (LA) function, which as they imply, were neglected in myState-of-the Art review (2). Calibrating the completeness of these
reviews can be problematic and requires balancing the novelty of a
method with its demonstrated validity and clinical utility. Tissue-
tracking cardiac magnetic resonance (FT-CMR) is a new and
potentially useful technique for measuring strain from routine cine
CMR images using feature-tracking algorithms that were initially
designed for echocardiographic strain analysis. FT-CMR tracks
motion of a tissue voxel using standard steady-state free precession
sequences and is simpler, more practical and available, and less time
consuming than other CMR-based strain techniques. However, as
Dr. Habibi and colleagues state in their letter, reproducibility and
repeatability data for FT-CMR ventricular strain measurements are
conﬂicting (1). More recently, in a study of 145 healthy volunteers,
global circumferential but not longitudinal strain showed reason-
able agreement with tagged CMR, with acceptable interobserver
reproducibility (2). In another study, there was considerable vari-
ability between FT-CMR and two-dimensional speckle tracking
echo strains of the right ventricle (RV) and left ventricle (LV) in
20 patients with tetralogy of Fallot and 20 control patients (3).
Importantly, reproducibility, variability, and validation data for
atrial FT-CMR (longitudinal) strain are nonexistent.
Moreover, there are no peer-reviewed studies of FT-CMR atrial
strain measurement. Indeed, the studies cited by Dr. Habibi and
colleagues are abstracts that have not, to date, undergone a rigor-
ous review process. Those studies concluded that addition of
FT-CMR LA strain helps distinguish subjects with atrial ﬁbrilla-
tion from controls; that FT-CMR peak systolic atrial strain, but
not LA volumes or emptying fraction, was associated with heart
failure after adjusting for NT-proBNP (N terminal pro brain
natriuretic peptide), traditional heart failure risk factors, and LV
mass; and that FT-CMR peak systolic LA strain and diastolic
strain rate are associated with signiﬁcant late gadolinium LV
myocardial scars (1). The FT-CMR ﬁeld is indisputably
inchoate; acquisition technique, cine sequence, ﬁeld strength, and
temporal resolution are variables that are likely to affect the accu-
racy and precision of FT-CMR measurements of atrial strain
using CMR. The need for further pre-clinical analysis in addi-
tion to clinical trials was trumpeted in a recent editorial (4).
Finally, the focus of my review was the role of LA function in
prognosis. Although it is tempting to extrapolate from the expe-
rience of echocardiographic LA strain, there are no studies of FT-
CMR LA strain that examine outcomes or that compare LA
strain measured with that of FT-CMR to echocardiography.*Brian D. Hoit, MD
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Concentration Increase
by Ticagrelor in Patients With
Acute Coronary Syndrome
No Cause for Fear in Clinical PracticeWe read with great interest the work by Bonello et al. (1). The
authors are to be commended for a very elegant study of acute
coronary syndrome (ACS) patients demonstrating an increase in
adenosine plasma concentration (APC) by ticagrelor compared to
clopidogrel through inhibition of adenosine uptake by red blood
cells and supporting the hypothesis of signiﬁcant off-target prop-
erties of ticagrelor. Although not speciﬁcally addressed in the
present study, increases in APC may represent an additional an-
tiplatelet mechanism for ticagrelor (2). More importantly, ﬁndings
by Bonello et al. (1) provide a causative, missing link for the dif-
ferential effects of ticagrelor versus those of prasugrel on coronary
blood ﬂow velocity (CBFV) during increasing doses of intrave-
nously administered adenosine, as reported by our group in 56 ACS
patients (3). Although the APC increase was described in blood
samples obtained 6 h post-antiplatelet loading, one could speculate
a higher availability of adenosine while receiving treatment with
ticagrelor rather than the prasugrel maintenance dose (MD), as
implicated for CBFV observed differences, and partially explaining
the long-term beneﬁcial effects seen with ticagrelor.
However, we strongly disagree with characterization of the use of
adenosine as a provocative test in patients taking ticagrelor as
“coronary ﬂow reserve (CFR) with a turbo” by Voci and Pizzuto
(4). No CFR differences have been observed in healthy male
subjects given 180 mg of ticagrelor or in ACS patients given MD
of ticagrelor compared with placebo or MD of prasugrel, respec-
tively (3,5). Differences in [maximum CBFV/baseline CBFV] in
favor of ticagrelor were apparent with incremental adenosine doses
but not at the highest infusion rate of maximal hyperemia. Voci and
Pizzuto (4) hypothesized that patients receiving either ticagrelor or
dipyridamole might have a supernormal response to standard
adenosine doses used for both therapeutic and diagnostic applica-
tions, and suggested that we may have to reduce the initial aden-
osine dose 4- to 5-fold. Both ticagrelor and dipyridamole may be
equilibrative nucleoside transporter 1 (ENT1) inhibitors but are not
the “same” (2). Dipyridamole is a much more potent inhibitor than
ticagrelor. When adenosine (7.1 mmol l-1) is added to whole blood,
it is detectable for 3 to 6 min and for >60 min in the presence
of ticagrelor or dipyridamole, respectively (2). In the case of tica-
grelor, the suggested 4- to 5-fold dose reduction of adenosine
(ie, <50 mg/kg/min) would result in 35% to 45% of maximal CBFVseen at peak hyperemia (3,5). Voci and Pizzuto (4) warn against the
use of adenosine as a provocative test in ticagrelor-treated patients,
which in our opinion, is not supported by available evidence. At
peak hyperemia, mean arterial pressure, heart rate, and double
product did not differ between ticagrelor- and prasugrel-treated
patients (3). Adenosine-induced dyspnea is indeed signiﬁcantly
augmented with ticagrelor on board, although it is self-limiting and
of questionable clinical relevance. Moreover, the asymptomatic,
transient, second-degree atrioventricular block that does not need
medical treatment observed infrequently during adenosine infusions
may be slightly more common in subjects taking ticagrelor (3,5).
We believe that the increased APC described in patients with
ACS given ticagrelor should not raise any evidence-based concern
by clinicians.*Dimitrios Alexopoulos, MD
Ioanna Xanthopoulou, MD
*Cardiology Department
Patras University Hospital
Rion 26500, Patras
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J Am Coll Cardiol 2013;61:723–7.ReplyAdenosine Plasma Concentration
Increase by Ticagrelor in Patients
With Acute Coronary Syndrome
No Cause for Fear in Clinical Practice
We read with interest the letter by Drs. Alexopoulos and Xantho-
poulou regarding our study published in the Journal (1) and the letter
by Voci and Pizzuto (2). In that study we demonstrated that in acute
coronary syndrome patients, ticagrelor was associated with a signiﬁ-
cant increase in adenosine plasma level through inhibition of reuptake
by red blood cells. This interesting property of the drug, beyond
P2Y12-ADP receptor blockade, may be of clinical signiﬁcance.
